HR Execs on the Move

Olympus Biotech Corporation

www.olympusbiotech.com

 
Olympus Biotech Corporation is a Hudson, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Elligo Health Research

Elligo Health Research helps speed new therapies to market by providing large numbers of patients and clinicians the opportunity to participate in clinical research. Elligo enables rapid and effective clinical trial enrollment and facilitates the study site operations so that clinicians can focus on their research. Our unique direct to patient model allows us to streamline patient identification and qualification, site activation, patient enrollment, study initiation and study conclusion for more efficient and cost-effective trials.

AlliancePharma

The vision of AlliancePharma Inc. is to offer a service that is human, professional and personalized, and fosters the development of the skills of the replacement pharmacists and pharmacy technicians. In the long term, AlliancePharma Inc. strives to increase and improve the value of its privileged position in the area of pharmacy replacement services, as well as diversifying its activities in high value added sectors linked to health.

Centaur Pharmaceuticals

Centaur Pharmaceuticals is a Sunnyvale, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ratio Therapeutics

A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancer. Ratio Therapeutics` Trilliumâ„¢ targeting scaffold combines pharmacokinetic modulation with best-in-class chelation technology to create proprietary small molecule targeting agents to attack a broad array of cancer targets. Our compounds accommodate imaging and therapeutic radioisotopes, ie "theranostics". The tunable nature of our platform combined with small-scale imaging trials in patients results in accelerated, de-risked compound selection.